Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06412497 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

StatusRecruiting
PhasePhase 2
Started2024-06-05
View on ClinicalTrials.gov ↗

Amendment history

2026-06-02
Study Status, Contacts/Locations v3
Study sitescontacts updated at 1 of 1 site
2025-06-18
Study Status v2
Re-verified, no change to tracked fields
2024-06-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-07-01→confirmed 2024-06-05
Study sites0→1
2024-05-09
Original filing
A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.
Trial Details
NCT Number NCT06412497
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Enrollment 60 participants
Start Date 2024-06-05
Primary Completion 2035-05-01 (estimated)
Study Completion 2036-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03